Latest Breaking News On - Wolfgang schiessl europe - Page 1 : comparemela.com

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

Daiichi Sankyo Europe GmbH: Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation

Daiichi Sankyo Europe GmbH: First-in-class cholesterol-lowering treatment NILEMDO - (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI

Daiichi Sankyo Europe GmbH: First-in-class cholesterol-lowering treatment NILEMDO - (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI - (bempedoic acid and ezetimibe) tablet approved in Switzerland (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients - - Bempedoic acid and its fixed combination drug product with ezetimibe both deliver significant reductions in LDL-C when added to a statin or other lipid-lowering therapies 1,2 - Two-thirds of patients in Switzerland with very high cardiovascular risk do not achieve LDL-C target values set out by the European Society of Cardiology,